Lartruvo (olaratumab)
ConditionalAccelerated assessmentAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- olaratumab
- Company
- Eli Lilly Nederland B.V.
- Status
- Revoked
- Therapeutic area
- Sarcoma
- CHMP opinion
- Thu 15 Sep 2016
- EU approval
- Wed 09 Nov 2016
- Designations
- Conditional, Accelerated assessment, Additional monitoring
- Application
- EMEA/H/C/004216
- ATC
- L01XC27
- Official record
- www.ema.europa.eu
Indication
Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).
Regulatory milestones
No milestones recorded in the last year.
Follow Lartruvo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.